Background Several disease-modifying drug therapies are available for the treatment of multiple sclerosis (MS). To ensure the most appropriate MS management, we assessed the effectiveness and cost-effectiveness of the disease-modifying medicines used for MS. Methods We conducted a systematic review including 11 disease-modifying drugs used for treatment of adult patients diagnosed with relaps...

Beta interferon − INF 1b: Betaferon® and Extavia® (vial 250 g) INF 1a: Avonex® (vial 30 g); Rebif® (vial 22–44 g). Both also in syringes and preloaded containers. RR MS Pseudo-fever syndrome, depression, psychiatric disorders, moderate myelosuppression, hypotension, high liver enzymes, cough, dyspnea, proteinuria, OHT, hyperuricemia, KI, neuropathy, confusion, edema, hair loss, digestive altera...

BACKGROUND Due to the preventive nature of disease-modifying therapies for multiple sclerosis, treatment success particularly depends on adherence to therapeutic regimens and patients' perception of treatment efficacy. The latter is strongly influenced by the confidence in the involved health care professionals and the relationship to the treating physician. METHODS In this report, we conside...

INTRODUCTION Symptoms of multiple sclerosis (MS) are associated with significant and progressive functional disability and have a profound impact on patients' quality of life (QoL). QoL and daily life activities are two areas that suffer major changes during the course of MS and there are currently no questionnaires specifically designed to evaluate these areas in MS patients. PURPOSE To eval...

background:  multiple  sclerosis  (ms) patients permanently confronted  with serious challenges from treatment regimen. developing  a new  questionnaire in ms management, through  evaluation  of patients’ perspectives   and  knowledge   regarding   treatment  will help  to  identify the  sources  of tension, and  to  build  a therapeutic   alliance.   we   purposed   to   describe    ms patient...